A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

Name: A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
Creator: Vivli
Published: 2025-12-16 15:14:08
License: 暂无描述

DataCite Commons2025-12-16 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00012272/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.

提供机构：

Vivli

创建时间：

2025-12-16